Tresiba – Novo Nordisk’s new diabetes drug has been finally approved by the United States Food and Drug Administration this week, after being rejected for 2 years.
Moreover, the FDA also approved Ryzodeg, another drug produced by Novo Nordisk, which combines Tresiba with a more efficient form of insulin. This insulin injection has a long action effect.
Danish pharmaceutical company Novo Nordisk is known as the world leading producer of insulin. The hormone is produced by the pancreas and it transforms glucose into energy.
The first drug, Tresiba has already been approved in 30 countries across the world, and is a healthy business, considering that Nova Nordisk is expected to sell nearly $2.5 billion worth of drugs annually starting next decade.
However, Nova Nordisk was aware that the United States market for insulin accounts for more than 80% of the total global market, and it decided to sell their drug to Americans as well. Analysts are expecting a decent price for the new medicine.
Back in 2013, the Food and Drugs Administration declined Tresiba because they had considered there was not sufficient data on heart attack problems and side-effects of the drug.
Novo Nordisk’s drug will now complete with two other long lasting insulin medication sold by their main rival, the French Sanofi. The two drugs are called Toujeo and Lantus. Toujeo was also approved by the FDA earlier this year, while Lantus has a history of 15 years in the United States.
Novo Nordisk declared that their new insulin drug would last diabetics for as long as 42 hours, before they are needed to take another dose. This is good news. Their older drug, Levemir, had only a 20 to 24 hours effect. Since Tresiba is far more durable than any other drug that is currently on the market, Nova Nordisk categorized it as a premium drug and it will be sold at a higher price than Levemir. However, the company has not yet decided what would the best price be for the United States.
The company’s officials claimed that they want to do the drug as affordable as possible, considering the number of American diabetic patients.
The multinational Novo Nordisk stated that they will launch the drug in the United States in the first quarter of the next year, while Ryzodeg’s launch date has not yet been scheduled. The company declared that Tresiba’s cardiovascular side-effects results will conclude sometime next year.
Photo credits: Freestockphotos